6 [25] W. L. Ince, A. M. Jubb, S. N. Holden et al., “Association of k-ras, b-raf, and p53 status with the treatment eﬀect of bevacizumab,” Journal of the National Cancer Institute, vol. 97, no. 13, pp. 981–989, 2005. [26] L. Zahiragic, C. Schliemann, R. Bieker et al., “Bevacizumab reduces VEGF expression in patients with relapsed and refrac- tory acute myeloid leukemia without clinical antileukemic activity,” Leukemia, vol. 21, no. 6, pp. 1310–1312, 2007. [27] Y. Shaked, A. Ciarrocchi, M. Franco et al., “Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors,” Science, vol. 313, no. 5794, pp. 1785–1787, 2006. [28] C. Porta, J. Bellmunt, T. Eisen, C. Szczylik, and P. Mulders, “Treating the individual: the need for a patient-focused approach to the management of renal cell carcinoma,” Cancer Treatment Reviews, vol. 36, no. 1, pp. 16–23, 2010. [29] B. I. Rini, D. P. Cohen, D. R. Lu et al., “Hypertension as a biomarker of eﬃcacy in patients with metastatic renal cell carcinoma treated with sunitinib,” Journal of the National Cancer Institute, vol. 103, no. 9, pp. 763–773, 2011. [30] K. Huang, C. Andersson, G. M. Roomans, N. Ito, and L. Claesson-Welsh, “Signaling properties of VEGF receptor-1 and -2 homo- and heterodimers,” International Journal of Biochemistry and Cell Biology, vol. 33, no. 4, pp. 315–324, 2001. [31] J. Dixelius, T. Ma¨kinen, M. Wirzenius et al., “Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-3) heterodimerization with VEGFR-2 in primary lymphatic endothelial cells regulates tyrosine phosphorylation sites,” Journal of Biological Chemistry, vol. 278, no. 42, pp. 40973– 40979, 2003. [32] M. Autiero, J. Waltenberger, D. Communi et al., “Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1,” Nature Medicine, vol. 9, no. 7, pp. 936–943, 2003. [33] Y. Cao, L. Wang, D. Nandy et al., “Neuropilin-1 upholds dediﬀerentiation and propagation phenotypes of renal cell carcinoma cells by activating Akt and sonic hedgehog axes,” Cancer Research, vol. 68, no. 21, pp. 8667–8672, 2008. [34] N. Ferrara and W. J. Henzel, “Pituitary follicular cells secrete a novel heparin-binding growth factor speciﬁc for vascular endothelial cells,” Biochemical and Biophysical Research Com- munications, vol. 161, no. 2, pp. 851–858, 1989. [35] N. Ferrara, K. A. Houck, L. B. Jakeman, J. Winer, and D. W. Leung, “The vascular endothelial growth factor family of polypeptides,” Journal of Cellular Biochemistry, vol. 47, no. 3, pp. 211–218, 1991. [36] K. A. Houck, N. Ferrara, J. Winer, G. Cachianes, B. Li, and D. W. Leung, “The vascular endothelial growth factor family: identiﬁcation of a fourth molecular species and characterization of alternative splicing of RNA,” Molecular Endocrinology, vol. 5, no. 12, pp. 1806–1814, 1991. [37] L. Jingjing, Y. Xue, N. Agarwal, and R. S. Roque, “Human Muller cells express VEGF183, a novel spliced variant of vas- cular endothelial growth factor,” Investigative Ophthalmology and Visual Science, vol. 40, no. 3, pp. 752–759, 1999. [38] Z. Poltorak, T. Cohen, R. Sivan et al., “VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix,” Journal of Biological Chemistry, vol. 272, no. 11, pp. 7151–7158, 1997. [39] C. Whittle, K. Gillespie, R. Harrison, P. W. Mathieson, and S. J. Harper, “Heterogeneous vascular endothelial growth factor (VEGF) isoform mRNA and receptor mRNA expression in human glomeruli, and the identiﬁcation of VEGF148 mRNA, a novel truncated splice variant,” Clinical Science, vol. 97, no. 3, pp. 303–312, 1999. Journal of Nucleic Acids [40] P. Mineur, A. C. Colige, C. F. Deroanne et al., “Newly identiﬁed biologically active and proteolysis-resistant VEGF-A isoform VEGF111 is induced by genotoxic agents,” Journal of Cell Biology, vol. 179, no. 6, pp. 1261–1273, 2007. [41] D. O. Bates, T. G. Cui, J. M. Doughty et al., “VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma,” Cancer Research, vol. 62, no. 14, pp. 4123–4131, 2002. [42] S. J. Harper and D. O. Bates, “VEGF-A splicing: the key to anti- angiogenic therapeutics?” Nature Reviews Cancer, vol. 8, no. 11, pp. 880–887, 2008. [43] T. G. Cui, R. R. Foster, M. Saleem et al., “Diﬀerentiated human podocytes endogenously express an inhibitory isoform of vascular endothelial growth factor (VEGF165b) mRNA and protein,” American Journal of Physiology—Renal Physiology, vol. 286, no. 4, pp. F767–F773, 2004. [44] J. Woolard, W. Y. Wang, H. S. Bevan et al., “VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo eﬀect on angiogenesis and endogenous protein expression,” Cancer Research, vol. 64, no. 21, pp. 7822–7835, 2004. [45] A. H. R. Varey, E. S. Rennel, Y. Qiu et al., “VEGF165b, an antiangiogenic VEGF-A isoform, binds and inhibits beva- cizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy,” British Journal of Cancer, vol. 98, no. 8, pp. 1366–1379, 2008. [46] R. Catena, L. Larzabal, M. Larrayoz et al., “VEGF121b and VEGF165b are weakly angiogenic isoforms of VEGF-A,” Molecular Cancer, vol. 9, p. 320, 2010. [47] E. S. Rennel, E. Waine, H. Guan et al., “The endogenous anti- angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice,” British Journal of Cancer, vol. 98, no. 7, pp. 1250–1257, 2008. [48] E. S. Rennel, M. A. Hamdollah-Zadeh, E. R. Wheatley et al., “Recombinant human VEGF165b protein is an eﬀective anti- cancer agent in mice,” European Journal of Cancer, vol. 44, no. 13, pp. 1883–1894, 2008. [49] J. Hua, C. Spee, S. Kase et al., “Recombinant human VEGF165b inhibits experimental choroidal neovasculariza- tion,” Investigative Ophthalmology and Visual Science, vol. 51, no. 8, pp. 4282–4288, 2010. [50] A. L. Magnussen, E. S. Rennel, J. Hua et al., “VEGF-A165b is cytoprotective and antiangiogenic in the retina,” Investigative Ophthalmology and Visual Science, vol. 51, no. 8, pp. 4273– 4281, 2010. [51] R. O. Pritchard-Jones, D. B. A. Dunn, Y. Qiu et al., “Expression of VEGFxxxb, the inhibitory isoforms of VEGF, in malignant melanoma,” British Journal of Cancer, vol. 97, no. 2, pp. 223– 230, 2007. [52] R. M. Perrin, O. Konopatskaya, Y. Qiu, S. Harper, D. O. Bates, and A. J. Churchill, “Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor,” Diabetologia, vol. 48, no. 11, pp. 2422–2427, 2005. [53] Y. A. Muller, Y. Chen, H. W. Christinger et al., “VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface,” Structure, vol. 6, no. 9, pp. 1153– 1167, 1998. [54] K. Miller, M. Wang, J. Gralow et al., “Paclitaxel plus beva- cizumab versus paclitaxel alone for metastatic breast cancer,” New England Journal of Medicine, vol. 357, no. 26, pp. 2666– 2676, 2007.